Genitourinary Cancers | Clinical

Investigators Examine Biomarkers of Response to Avelumab in Urothelial Carcinoma

September 20, 2020

Biomarkers of immune activity were linked with overall survival benefit to frontline maintenance avelumab in patients with advanced urothelial cancer, according to data presented at the ESMO Virtual Congress 2020 from an exploratory analysis of the phase 3 JAVELIN Bladder 100 trial.

Sacituzumab Govitecan Sustains Clinical Activity in Patients With Heavily Pretreated mUC

September 20, 2020

Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC

May 31, 2020

Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.

DFS Improvement Falls Short With Anti–PD-L1 in Muscle-Invasive Urothelial Cancer

May 31, 2020

"Irrespective of the PD-L1 status, there were no trends in favor of atezolizumab in both arms."

Combination Therapy With Cabozantinib and Atezolizumab Gains Foothold in Urothelial Carcinoma

May 30, 2020

Patients with urothelial carcinoma who progress after platinum-containing chemotherapy may receive benefit with the combination regimen of cabozantinib and atezolizumab, according to new data from the COSMIC-021 study.

UGN-102 May Serve as Surgical Alternative for Low-Grade NMIBC With Intermediate Risk

May 15, 2020

"These interim data demonstrate that primary chemoablation of low-grade intermediate-risk non–muscle invasive bladder cancer using UGN-102 results in a significant treatment response and encouraging durability."

BCG-Unresponsive NMIBC Responds to Intravesical Adenoviral Gene Therapy

May 15, 2020

"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."

Combining Immune Checkpoint and Androgen Receptor Inhibitors Yields Positive Responses for mCRPC

April 11, 2020

Pembrolizumab plus enzalutamide in castration- resistant prostate cancer that exhibited enzalutamide resistance led to positive antitumor signals and a favorable safety profile, according to results of the phase II KEYNOTE-199 trial presented at the 2020 Genitourinary Cancers Symposium.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 07, 2020

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Real-World PSA Response Data Similar to Clinical Trials in Prostate Cancer

April 07, 2020

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.